ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2296

Platelet Release Products Mediate Endothelial Apoptosis: A Possible Role for Thrombospondin 1- CD36 Pathway in SSc-Endothelial Apoptosis

Bashar Kahaleh1 and Yongqing Wang2, 1Medicine/Rheumatology, University of Toledo, Toledo, OH, 2Medicine, University of Toledo, Toledo, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Apoptosis, endothelial cells and platelets

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Sequential pathologic observations in the early stages of SSc demonstrated evidence for platelet aggregation and binding to blood vessels that is generally followed by vascular effacement and the development of SSc vasculopathy. In this study we thought to investigate the effects of platelet constituents on microvascular endothelial cells (MVEC) apoptosis. We particularly investigated the role of thrombospondin 1 (TSP1) as a possible platelet derived signal since it is a potent angiogenic inhibiter, it can mediate endothelial apoptosis and activate TGF-β and is reported to be overexpressed in SSc. Furthermore, we investigated the role of CD36 in MVEC apoptosis since TSP1 vascular effects are known to results from its binding to CD 36 receptors.

Methods:

MVEC were isolated from involved SSc skin and from match healthy control subjects. Platelets were collected from healthy subjects, sonicated, ultracentrifuged and the resulting supernatant (PLSN) was used in MVEC cultures. MVEC apoptosis was evaluated by TUNEL and active caspases-3 staining.  CD 36 expression in MVEC was measured by quantitative RT-PCR and CD36 expression was knocked down using CD36 specific siRNA.

Results:

The following results were observed in this study:

  1. Addition of PLSN to MVEC cultured in 0.5% serum concentration resulted in a dose dependent apoptosis of MVEC. SSc-MVEC were more susceptible to apoptosis than control MVEC, thus at 20% PLSN concentration, MVEC apoptosis was 20% ± 5 and 48% ± 8 in control vs SSc MVEC respectively (mean ± SD of three cell lines).
  2. Addition of TSP1 neutralizing antibody to PLSN significantly reduced PLSN induced MVEC apoptosis, suggesting that TSP1 in PLSN mediate MVEC apoptosis.
  3. CD 36 expression levels were significantly higher in SSc MVEC than in control MVEC (7.4 ± 2.3 folds, mean ± SD of 3 cell lines)
  4. CD36 knock down using CD36 specific siRNA but not ir-siRNA resulted in > 90% decrease in CD36 expression and the inhibition of TSP1 and PLSN induced MVEC apoptosis.  

Conclusion: Platelets interaction with MVEC results in MVEC apoptosis. This effect is largely mediated by interaction of TSP1 with CD36.  SSc-MVEC are more susceptible to this effect possibly because of an upregulated CD36 expression in SSc-MVEC. The data propose the platelet as a possible source for the initial MVEC apoptotic signal in the early stages of SSc vasculopathy and suggest TSP1 as a crucial player in SSc pathogenesis in view of its abundance in SSc and its documented role in the genesis of vasculopathy and tissue fibrosis


Disclosure:

B. Kahaleh,
None;

Y. Wang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/platelet-release-products-mediate-endothelial-apoptosis-a-possible-role-for-thrombospondin-1-cd36-pathway-in-ssc-endothelial-apoptosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology